Pfizer
Pfizer is a global research-based biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of medicines and vaccines. The company focuses on delivering innovative treatments across various therapeutic areas, including oncology, immunology, and infectious diseases, while navigating highly regulated global markets. Its core value proposition centers on leveraging large-scale R&D investment to address significant unmet medical needs and maintaining a differentiated product pipeline.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Biopharmaceutical Products
primaryThe primary business unit focused on the research, development, and sale of branded prescription medicines and vaccines across multiple therapeutic areas.
Eliquis, Ibrance, Xtandi, Xeljanz, Enbrel
Wholesalers, Retailers, Hospitals, Government agencies, Managed care organizations
Biosimilars
moderateA specialized portfolio of biologic medicines that are highly similar to already approved reference products, offering lower-cost alternatives in areas like oncology and immunology.
Biosimilars of inflammation & immunology medicines, Oncology biosimilars
Health plans, Hospitals, Government healthcare programs
Segment Financials
Biopharma — Investment Income, Dividend
View metricTotal Alliance revenues — Alliance revenues
View metricTukysa — Finite-lived intangible assets, period increase
View metricBusiness Overview
Competitive Position
A leading global biopharmaceutical innovator that competes on the basis of efficacy, safety, and the ability to maintain market exclusivity through robust intellectual property protection.
Geographies
United States, European Union, China, Japan, United Kingdom
Customer Segments
Healthcare Providers, Government Entities, Patients, Payors
Upstream Dependencies
Raw material suppliers, Contract research organizations, Specialized chemical manufacturers
Downstream Customers
Drug wholesalers, Pharmacy benefit managers (PBMs), Hospitals and clinics, Government health authorities, Retail pharmacies
Competitors & Partners
Competitors
Johnson & Johnson
JNJ
Global biopharmaceutical and vaccine competitor
Bristol-Myers Squibb
BMY
Competitor in oncology and cardiovascular treatments
Merck & Co.
MRK
Global research-based biopharmaceutical competitor
Amgen
AMGN
Competitor in oncology and inflammation.
AbbVie
ABBV
Competitor in immunology and oncology
Viatris
VTRS
Competitor in branded and innovative pharmaceutical markets
Eli Lilly
LLY
Global pharmaceutical competitor across multiple therapeutic areas
Revolution Medicines, Inc.
RVMD
Developing mutant RAS programs
Partners
World Health Organization
Collaborates on scientific opinions for high priority human medicines in markets outside the EU
Pfizer FAQ
Common questions about Pfizer
Pfizer is a global research-based biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of medicines and vaccines. The company focuses on delivering innovative treatments across various therapeutic areas, including oncology, immunology, and infectious diseases, while navigating highly regulated global markets. Its core value proposition centers on leveraging large-scale R&D investment to address significant unmet medical needs and maintaining a differentiated product pipeline.
Pfizer (PFE) has a market capitalization of $147.62B and trades on NYSE.
Pfizer generated $63.3B in trailing twelve-month revenue with net income of $12.1B, representing a net margin of 19.1%. Gross margin stands at 73.5%, with free cash flow of $12.5B. These figures are based on the Q1 2026 filing.
Pfizer's key competitors include Johnson & Johnson, Bristol-Myers Squibb, Merck & Co., and others. These companies compete in similar markets and product categories.
Pfizer has approximately 88,000 employees.